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Abstract
Background
Rift Valley fever virus (RVFV) is a zoonotic arbovirus that causes severe disease in livestock
and humans. The virus has caused recurrent outbreaks in Africa and the Arabian Peninsula
since its discovery in 1931. This review sought to evaluate RVFV seroprevalence across the
African continent in livestock, wildlife and humans in order to understand the spatio-tempo-
ral distribution of RVFV seroprevalence and to identify knowledge gaps and areas requiring
further research. Risk factors associated with seropositivity were identified and study
designs evaluated to understand the validity of their results.
Methodology
The Preferred Reporting of Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines were used to produce a protocol to systematically search for RVFV seropreva-
lence studies in PubMed and Web of Science databases. The Strengthening the Reporting
of Observational studies in Epidemiology (STROBE) statement guided the evaluation of
study design and analyses.
Principal findings
A total of 174 RVFV seroprevalence studies in 126 articles fulfilled the inclusion criteria.
RVFV seroprevalence was recorded in 31 African countries from 1968 to 2016 and varied
by time, species and country. RVFV seroprevalence articles including either livestock and
humans or livestock and wildlife seroprevalence records were limited in number (8/126). No
articles considered wildlife, livestock and human seroprevalence concurrently, nor wildlife
and humans alone. Many studies did not account for study design bias or the sensitivity and
specificity of diagnostic tests.
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Conclusions
Future research should focus on conducting seroprevalence studies at the wildlife, livestock
and human interface to better understand the nature of cross-species transmission of
RVFV. Reporting should be more transparent and biases accounted for in future seropreva-
lence research to understand the true burden of disease on the African continent.
Author summary
Rift Valley fever virus (RVFV) is a vector-borne virus that infects wildlife and livestock,
and can subsequently spread to humans. Due to the nature of the disease it has the poten-
tial to cause substantial economic and public health impacts. Rift Valley Fever (RVF) has
been identified in Africa and the Arabian Peninsula, but has the potential to spread more
widely. This systematic review assessed the distribution of RVF in livestock and humans
in Africa by collating all the relevant studies we could find, extracting the data and criti-
cally evaluating them. Understanding when and where RVF has occurred in Africa and
why some animals and humans get disease helps target control strategies and, in particu-
lar, those that reduce spread from livestock to humans. Furthermore, by evaluating past
studies we can ensure that future ones are more robust and reproducible, so they can help
us better understand the disease.
Introduction
Rift Valley fever virus (RVFV) is a zoonotic arbovirus that infects humans, livestock and wild-
life species. The disease it causes, Rift Valley fever (RVF), is a World Health Organisation for
Animal Health (OIE) listed disease and is a World Health Organisation (WHO) priority dis-
ease for research and development due to its potential to cause major epidemics in humans
[1]. RVF was discovered in 1931 on a farm in the Great Rift Valley of Kenya [2] and, to date, it
has only been reported in African countries and the Arabian Peninsula [3].
Epizootics of RVF are sporadic and are often linked to persistent heavy rainfall and flood-
ing, which causes the emergence of infected Aedes mosquitoes (hypothesised to have been
infected via transovarial transmission [4]), after which transmission is amplified by other mos-
quito species (such as of Anopheles and Culex genera) [5, 6]. This amplification can result in
subsequent spillover transmission from livestock to humans [7]. There has been very little
research assessing transmission from mosquitoes to humans [6], and the main route of trans-
mission is thought to be through contact with blood/tissue from infected livestock [8]. Inter-
vals when outbreaks are not occurring are known as interepidemic or interepizootic periods
(IEPs). During IEPs RVFV is believed to be maintained by transovarial transmission in Aedes
mosquitoes [4], enabling low-level circulation in wildlife and livestock [9]. It is unknown
whether wildlife species act as RVFV reservoirs, but seroconversion has been identified in mul-
tiple species [10].
Routine surveillance for RVFV in African countries is limited and outbreaks are underre-
ported [11]. Proxy measures such as the normalized difference vegetation index (NDVI), mon-
itoring of the El Niño Southern Oscillation (ENSO) events and the sea surface temperature
(SST) anomalies between Indian and Atlantic oceans have been used to predict when and
where RVF outbreaks may occur [12–14] although these predictions can be unreliable [15].
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Assessing historic and present RVFV seroprevalence in livestock and humans within African
countries provides evidence of where the virus may circulate and helps identify at-risk popula-
tions, potentially informing intervention strategies and resources allocation. This is important
because: (i) there is a global concern that RVFV is a pathogen that has the potential to cause
large scale epidemics [1]; (ii) in 2000 the geographical range of RVFV epidemics extended to
the Arabian peninsula [16] and (iii) the theoretical ease with which infection could be sus-
tained in other parts of the world due to favourable ecological conditions, including the pres-
ence of competent vectors [17–19]. By implementing control measures in at-risk populations
during inter-epidemic years, further dissemination of the disease can be prevented.
This review seeks to assess RVFV seroprevalence in wildlife, livestock and humans on the
African continent, particularly considering the relationship between these species and the risk
of RVFV spillover transmission. In order to do this comprehensively, a systematic review was
performed and the study designs of eligible articles were evaluated to examine how seropreva-
lence was measured and calculated, including potential sources of bias. Reviews of Rift Valley
fever epidemiology have evaluated the spatio-temporal, ecological, predictive risk factors and
modelling methods used in studies across Africa [3, 20–22]. Previous seroprevalence studies in
wildlife, livestock or humans have typically focused on a single time point, species and country.
This review will bridge these studies, identify associated trends in RVFV seroprevalence and
evaluate study designs.
Methods
The study protocol for this systematic review used the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines [23] (S1 Table). A search of published
studies on MEDLINE (PubMed) and Web of Knowledge was carried out on 8th January 2018;
all articles that could be accessed on these databases were considered for inclusion in the
review. Search terms used to identify articles were: ((“Rift Valley Fever” OR “RVF”) AND
(“prevalence” OR “incidence” OR “sero”)). Broad search terms were purposefully used to
maximise the chances of capturing all relevant research articles. Data extraction, screening and
analysis was carried out by a single user (MC), with co-authors providing advice when
required. An Excel spreadsheet was used to record data from eligible studies (S1 Dataset). Data
extracted included: (i) seroprevalence percentage (by species, year of study and country); (ii)
sample size; (iii) type of study; (iv) diagnostic and statistical tests used and (v) information on
study design.
For a research article to be included in the review it had to meet the following criteria: (i)
focused on an African country; (ii) provide original quantitative serological information on
RVFV in humans, livestock and/or wildlife; and (iii) be available in the English language. Stud-
ies were excluded if: they had utilised previously published seroprevalence datasets for further
analysis (including mathematical modelling), or they had not recorded the year of sampling
(Fig 1).
Seroprevalence was analysed separately for goats, sheep, cattle, camels and humans. How-
ever, seroprevalence was pooled for wildlife due to the large range of species surveyed. The
most common species tested was African buffalo (Syncerus caffer), but other species were sam-
pled including elephants, white and black rhinoceros, giraffe, lions, leopards, lesser kudu,
eland, kongoni, gazelle, impala, waterbuck and rodents [10, 24–32].
Where articles included multiple seroprevalence studies in different species or used differ-
ent types of study design, each study was considered separately for the seroprevalence-specific
analysis. However, articles reporting multiple seroprevalence studies did not account for bias
or diagnostic tests for each study individually and, therefore, the analysis of these aspects was
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conducted by article. The epidemic period (outbreak/IEP) for each article were recorded; if a
period wasn’t stated it was classed as an IEP. Outbreak and inter-epidemic periods were classi-
fied according to description in each individual article. If the period was not stated it was
classed as inter-epidemic period.
Epidemiological study designs should account for bias where possible. Published in 2007,
the STROBE statement is a valuable tool used to design and evaluate data analysis methods
[31]. Although eligible articles in this systematic review were published prior to the STROBE
statement, these guidelines were used to provide a standardised assessment of the design and
methods used for data analysis within the studies, as well as to assess the risk of different forms
of bias in the study design (randomisation, recruitment, eligibility, exclusion), statistical power
and statistical methods [31, 33].
RVFV seroprevalence distribution maps were created using the ggplot2 library [34] in R
(version 3.3.3) [35].
Results
A total of 126 articles met the inclusion criteria and reported RVFV seroprevalence (Fig 1).
Seventeen of the articles included multiple seroprevalence studies using different species and
types of study design. These were considered separately for the seroprevalence-specific analysis
yielding a total of 174 studies. Many of the excluded studies were review articles, related to
control policy or based on laboratory experiments.
Fig 1. Flowchart for the systematic review to identify eligible studies of Rift Valley fever virus (RVFV) seroprevalence in
Africa.
https://doi.org/10.1371/journal.pntd.0006627.g001
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Location and timing of RVFV seroprevalence studies in Africa
The earliest eligible study identified was carried out in 1968 [36]. Since then RVFV seropreva-
lence has been reported in 31 African countries (Fig 2). The focus of the majority of studies
has been in eastern Africa with 48/174 (27.6%) seroprevalence studies being in Kenya alone
(Fig 2).
Although the first study included was conducted in 1968, there was a gap of over a decade
before the next eligible study was conducted in 1979 (Fig 3). Since 1979 seroprevalence studies
have been carried out in most years (Fig 3). An increase in studies conducted for all species
was evident in the 2000s (Fig 3). The peak years for studies were 2007 and 2010 during which
reported outbreaks occurred [37]. Of the 174 studies, 141 (80%) were conducted during IEPs,
32 (18.2%) during outbreaks and one (0.6%) immediately after an outbreak.
More RVFV seroprevalence studies have been conducted in livestock species (77/174
[44.3%]) than humans (60/174 [34.5%]) or wildlife (40/174 [23%]). Over the last four decades
16/174 (9.2%) seroprevalence studies have been conducted in camels. All RVFV seropreva-
lence studies undertaken in wildlife species were conducted in IEPs and only in Zimbabwe,
South Africa, Senegal and Botswana.
Reported seroprevalence of RVFV
The seroprevalence of RVFV varied geographically and temporally in livestock, wildlife and
humans. These trends are summarised in Figs 4 and 5, while the full data are presented in S2
Table. Median RVFV seroprevalence was 12.9% in sheep (range 0–100%), 12.6% in cattle
(range 0–100%); 11.3% in wildlife (range 0–87.5%), 10.1% in goats (range 0–69.6%); 8.8%
in camels (range 0–57.1%) and 5.9% in humans (range 0–81.0%). The highest RVFV
Fig 2. Number and geographical distribution of Rift Valley fever virus (RVFV) seroprevalence studies in African
countries.
https://doi.org/10.1371/journal.pntd.0006627.g002
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seroprevalence in livestock was identified in sheep and cattle in Egypt during an epizootic in
1997, where 100% of samples were seropositive (93 cattle and 57 sheep) (S2 Table) [38]. RVFV
seroprevalence was significantly higher during outbreak periods compared to IEPs in goats
(Wilcox rank sum test, outbreak median = 50%, IEP median = 9.40%, p = 0.001) and sheep
(Wilcox rank sum test, outbreak median = 34.8%, IEP median = 12.9%, p = 0.01) but not in
cattle, camels or humans (Fig 5).
Only six studies examined RVFV seroprevalence in livestock and humans concurrently,
two studies examined seroprevalence between livestock and wildlife and no studies assessed
wildlife and humans together (Table 1). Given the overall small number of concurrent studies,
and limited information on links between species sampled, it is difficult to draw any conclu-
sions about the relationship between RVFV seroprevalence in humans, wildlife and livestock.
Diagnostic tests. Information provided about the diagnostic test used varied considerably
between articles (n = 126): 25/126 (19.8%) did not state any details regarding diagnostic tests
used; 64/126 (50.8%) described specific methods used; and 27/126 (21.4%) provided references
Fig 3. Number of Rift Valley fever virus (RVFV) seroprevalence studies conducted in African countries by year study was conducted.
https://doi.org/10.1371/journal.pntd.0006627.g003
Systematic literature review of Rift Valley fever virus seroprevalence in Africa
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006627 July 23, 2018 6 / 19
to articles which described the test. Only 12 articles gave the diagnostic sensitivity and specific-
ity of the tests (12/126 [9.5%]), seven of which used a commercial test [46–50].
Commercial and in-house ELISAs were used in the majority of articles (94/126 [74.6%]).
Virus neutralisation tests (VNTs) were used in a total of 32/126 articles (25.4%). In 17 of these
Fig 4. The distribution of seroprevalence (% individuals seropositive) for Rift Valley fever virus by species and decade in African countries, 1968–2016 (year study
was conducted).
https://doi.org/10.1371/journal.pntd.0006627.g004
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32 articles (53.1%) VNTs were used as a confirmatory test for the ELISAs, often only testing a
subset of the samples.
Fig 5. Reported seroprevalence (% individuals seropositive) of Rift Valley fever virus in (A) cattle, (B) sheep, (C) goats, (D) camels, (E) humans and (F) wildlife in African
countries, during 1968–2016 (year study was conducted). Symbols indicate whether studies were reported as being carried out during outbreaks (filled yellow squares),
immediately after outbreaks (filled back diamonds) or during inter-epidemic periods (filled blue circles).
https://doi.org/10.1371/journal.pntd.0006627.g005
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Risk factors for RVFV seropositivity
In total, 41/126 eligible articles (32.5%) presented records of RVFV seroprevalence without
any statistical analyses. The most common statistical method to compare seropositivity
between groups used in the remaining articles was the univariate χ2 test, which was the sole
test used in 10/126 (8%) articles. Multivariate analysis was conducted in 23/126 (18.2%) of arti-
cles to establish whether multiple factors influenced RVFV seropositivity.
Several risk factors were significantly associated with seropositivity to RVFV in both
humans and livestock in particular increasing age (Tables 2 & 3). Occupations and practices
associated with handling of animal blood/tissue were also identified as risk factors for seropos-
itivity in humans (Table 2). Contradictory associations between risk and sex were reported,
with some studies reporting an increased risk in males [7, 51, 52], some reporting a decreased
risk in males [53, 54] and yet others finding no association [55]. The seroprevalence of RVFV
was significantly higher in sheep than in other species (Table 3) [22, 42, 55, 56].
Assessment of biases in RVFV seroprevalence studies
For seroprevalence records (n = 174), the majority of studies in the systematic review were
cross-sectional (149/174 [85.6%]); 20/174 (11.5%) were longitudinal studies; 3/174 (1.7%) were
Table 1. RVFV seroprevalence studies conducted in livestock, humans or wildlife concurrently.
% species seropositive
Country Year African
buffalo
Humans Goats Sheep Cattle Link between populations Ref.
Senegal 1989 - 22.3 - 30.1 - Human samples were taken from sheep owners [39]
Madagascar 1990 - 5.4 - - 29.6 None reported [40]
Mauritania 1998 - 24.4 16.3 34.8 - None reported [41]
Central African
Republic
2010 - 16.7 5.0 12.9 7.8 Samples taken from animals and humans at the same villages, livestock
markets and slaughterhouses
[42]
Mayotte 2010 - 4.1 22.4 22.4 26.8 None reported [43]
Kenya 2010 - 1.4 - - 0.5 Linkage was identified in some households sampled [44]
Zimbabwe 2008 5.3 - - - 12.1 Unfenced interfaces. Informal interviews stated buffalo are often seen at
these sites
[24]
Botswana 2010 12.7 - - - 5.7 Cattle sampled based on proximity to protected area (where buffalo may be
present)
[24,
45]
https://doi.org/10.1371/journal.pntd.0006627.t001
Table 2. Number of eligible articles in humans in Africa identifying potential risk factors as significantly associated with seropositivity for Rift Valley fever virus
(RVFV) in final statistical model.
Number of articles using statistical methods (out of 51
eligible articles)
Risk factors for seropositivity to RVFV† Univariate Multivariate References
Age †† 5 11 [40, 54, 57–70]
Sex 2 5 [7, 43, 52, 54, 60, 71–73]
Occupation 1 2 [8, 58, 74]
Contact with livestock foetus 0 2 [8, 73]
† risk factors were only included in this table if they were found to be significant in at least two articles
††RVFV seroprevalence increased with age
sex was identified as a risk factor for RVFV seroposivity in a number of studies, but the conclusions were contradictory (see text)
occupations involving contact with animal blood and products were associated with an increased risk
https://doi.org/10.1371/journal.pntd.0006627.t002
Systematic literature review of Rift Valley fever virus seroprevalence in Africa
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006627 July 23, 2018 9 / 19
case-control studies [85, 86]; and 2/174 (1.1%) were cohort studies [87, 88]. Few of the eligible
articles (n = 126) in this systematic review accounted for bias (Table 4) and only one article
[89] accounted for all five potential sources of bias outlined by the STROBE statement
(Table 4) [31]. Eligibility and exclusion criteria as well as power calculations were seldom
reported in the articles. A range of random sampling schemes were used [43, 53, 78, 81, 90–97]
although the majority of articles did not specify the randomisation protocol (94/126 [74.6%]).
History of vaccination status of livestock was not reported in 37/51 (72.5%) livestock seroprev-
alence eligible articles.
Discussion
Over the last four decades there has been an increasing number of RVFV seroprevalence stud-
ies carried out in wildlife, livestock and humans in Africa (Fig 3). There have been a number of
RVFV outbreaks during the 2000s, which may have resulted in an increase in RVF awareness
and resources for surveillance leading to an increase in seroprevalence studies during IEPs
(Fig 3). There is, however, limited geographical coverage of RVFV studies: some countries in
North and East Africa have not reported outbreaks or assessed seroprevalence (Figs 2 & 4).
This is relevant from an epidemiological perspective since RVFV has been detected in other
countries within these regions, thus increasing the likely risk of viral incursions through ani-
mal trade which has been implicated as the main route of virus dissemination in several out-
breaks [43, 98, 99]. The risk posed by animal trade also suggests that cross-border surveillance
in both livestock and humans is required to add to the understanding and significance of this
route for RVFV transmission.
A number of countries have conducted very few seroprevalence studies (Fig 4; S2 Table)
which makes it difficult to assess temporal trends. In those countries where more studies were
conducted, temporal trends are indicitative of recurrent outbreaks (for example Comoros,
Table 3. Number of studies on livestock in Africa identifying potential risk factors as significantly associated seropositivity for Rift Valley fever virus (RVFV).
Number of articles using statistical methods (out of 70
eligible articles)
Risk factors for seropositivity to RVFV† Univariate Multivariate References
Age†† 7 8 [39, 42, 50, 51, 55, 75–83]
Species 5 1 [22, 42, 55, 56, 78, 84]
Sex 1 1 [51, 53]
Animal introduced into herd 1 1 [50, 79]
Nearby water point 0 2 [43, 76]
† risk factors were only included in this table if they were found to be significant in at least two articles
sex was identified as a risk factor for RVFV seropositivity in a number of studies, but the conclusions were contradictory (see text)
††RVFV seroprevalence increased with age
https://doi.org/10.1371/journal.pntd.0006627.t003
Table 4. Number of Rift Valley fever virus seroprevalence articles in Africa accounting for risk of bias outlined in the STROBE statement.
Species Randomisation Recruitment Exclusion Eligibility Power calculation for sample size
Livestock 20 35 2 5 13
Humans 13 31 8 18 6
Livestock and Humans 1 1 1 2 0
Wildlife 0 8 0 0 0
Total (% of 126 eligible studies) 34 (27) 75 (59.5) 11 (8.7) 25 (19.8) 19 (15.1)
https://doi.org/10.1371/journal.pntd.0006627.t004
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Mayotte, Kenya, Senegal or Mauritania) (S2 Table). However, caution is warranted when iden-
tifying trends from a series of cross-sectional studies. For example, those studies in Mayotte
were cross-sectional and undertaken in different districts of the country, and thus different
environments, which may have an impact on viral maintenance, transmission, and, hence,
seropositivity [99]. Similarly, in Kenya several studies were conducted on the same species in
the same year, but variation in seroprevalence within years may be indicative of specifics to the
study (location, age of animals/humans, study design, tests used).
The higher RVFV seroprevalences seen in animals compared to humans (Fig 5) may be a
consequence of differing forces of infection (i.e. transmission only occuring as a spillover
event in humans and thus risk of transmission is much lower). The significantly higher sero-
prevalence during outbreak years compared to interepidemic years seen in sheep and goats,
but not in other species, is likely due to the faster population turnover in sheep and goats,
which means there is a bigger pool of susceptibles to become infected between IEPs and out-
break periods. It has been suggested previously that wildlife species may act as reservoirs of the
virus. The high RVFV seroprevalence recorded in wildlife during IEPs supports this statement
and provides a basis that low level circulation may be taking place in these species [100].
The lack of seroprevalence studies in wildlife over the last decade suggests this is a neglected
area of research. Such studies are essential for further understanding the role of wildlife in viral
maintenance and potential spillover into livestock animals, particularly during outbreak peri-
ods. Indeed, to understand the impact of cross-species transmission, seroprevalence studies
should ideally be conducted concurrently in livestock, wildlife and humans. This would allow
the force of infection between species to be estimated and, hence, the relative importance of
different species in the transmission dynamics of RVFV. Yet the results of this systematic
review indicate that such studies are seldom carried out and, even when they are, the relevant
linkage between the species are not recorded (Table 1). A complete picture of cross-species
transmission would also require consideration to be given to mosquito species present and
their host feeding preferences [9].
A number of risk factors for human RVFV seropositivity were associated with contact prac-
tices with livestock (Table 2) and further research on risk factors in livestock may indicate
measures that could reduce spillover of infection into humans. A pragmatic approach would
seek to understand virus maintenance, especially within the environment, vectors and wildlife
populations to aid in targeting potential risk factors of RVFV seropositivity in livestock.
RVFV-induced abortions are a recognised clinical sign of the disease in livestock and, recently,
a study has found associations between miscarriages in women and infection with RVFV
[101]. This demonstrates the need for further research and implicates another at-risk
population.
The true seroprevalence of RVFV is often uncertain due to three factors affecting interpre-
tation of published seroprevalence studies. First, most studies do not provide enough informa-
tion on the diagnostic tests used including their sensitivity and specificity. If this information
is provided it is possible to estimate the true prevalence (i.e. allowing for false positive and false
negative results) from the apparent prevalence [102]. As a commercial assay, the ID Screen
RVFV competition multispecies ELISA (ID-Vet, Montpellier, France) used in many of the
studies was validated by carrying out a ring trial, which demonstrated that the test has a high
specificity (100%) and sensitivity (ranged from 91–100%) [103]. An inhibition ELISA was also
commonly used which has been shown to provide 100% sensitivity, and 99.29% and 100%
specificity in sheep and camels, respectively [104]. This suggests that for these tests there is a
low probability of false positives or false negatives and, hence, the apparent prevalence will be
a reasonable approximation of the true seroprevalence. However, reporting the diagnostic
test used and its sensitivity and specificity would be a recommendation for future RVFV
Systematic literature review of Rift Valley fever virus seroprevalence in Africa
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prevalence studies. Second, there are currently no commercial vaccines that are compliant
with tests that are able to differentiate between vaccinated and infected animals (DIVA),
meaning vaccinated animals will be classified as seropositive and, hence, the true seropreva-
lence could be overestimated. Thus vaccination history of recruited animals needs to be
recorded in the study design. Third, antibody responses to RVFV infection are long lived with
RVFV-specific antibodies having been reported in humans over 12 years after the only known
exposure [105, 106]. Consequently, serological assays are unable to confirm when exposure
took place [107–109]. Two possible ways of assessing the level of recent infection would be
through IgM ELISAs (IgM antibodies are short-lived for RVFV, which would be ideal for
showing endemic virus circulation) [110] or through use of RT-PCR to detect RVFV RNA
[111].
This review has highlighted the potential for bias in the designs of many RVFV seropreva-
lence studies, further complicating their interpretation. In many studies there was a lack of
randomisation, recruitment criteria or insufficient sample sizes. Recruitment is important in
understanding disease transmission in livestock, particularly with regard to animal trade histo-
ries and where animals have been exposed to the virus prior to the study (e.g. somewhere
other than the study locations). Many studies omitted information on livestock characteristics
such as age, sex and breed, all of which are factors that could influence interpretation of RVFV
seroprevalence results. There is a need to improve study design reporting to provide validity,
transparency and reproducibility. By implementing standardised methods, data can be objec-
tively examined and compared [112, 113].
The RVFV seroprevalence distributions visualised in the maps were pooled by country and
decade (Fig 1 and Fig 4). These maps provide an overview of seroprevalence on the African
continent, showing the variation both between countries over the same time period and within
countries over different time periods. However, it should be borne in mind that this could
mask heterogeneity in seroprevalence within a country, which reflects processes at smaller geo-
graphical, spatio-temporal and epidemiological scales [21] (for example within year variation
of seroprevalence in Kenya due to sampling in different regions of the country). Pooling the
wildlife species introduced a bias in itself, but this was done to provide a representation of
what seroprevalence is seen in wildlife, particularly as little research has been done on this.
This systematic review followed PRISMA guidelines [23] to provide a comprehensive unbiased
overview and collection, although some articles may have been missed due to only including
studies published in the English language (Fig 1).
One third of articles included in this systematic review did not conduct any statistical analy-
sis of the data they generated. This limits their usefulness in terms of both supporting evi-
dence-based decision making and furthering the understanding of the disease. Other studies
have identified risk factors associated with seropositivity to RVFV (Tables 2 and 3). However,
the level of significance (e.g. cut off p-values) required for something to be deemed a risk factor
varied across articles. Moreover, there were conflicting reports of statistical significance for
risk factors amongst studies. This could be explained by: the heterogeneity of study design; the
complex nature of different environments and the impact this has on the ability of the virus to
transmit; the methodology of the operator conducting the diagnostic tests; or those that may
have occurred by chance.
The contradictory relationship with sex and the risk of seropositivity may reflect differences
in local culture surrounding gender and animal handling/management practices. Understand-
ing the social aspect of disease transmission could provide valuable information to disease
spillover dynamics. The risk of seropositivity increased with age in both humans and livestock.
This most likely reflects the increase probability of exposure with age rather than implying
age-dependent susceptibility. Where the risk of seropositivity was found to differ significantly
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amongst livestock species, sheep were at increased risk in a number of studies, again presum-
ably due to the high population turnover, and also differences in susceptibility or host immune
response, vector host preference or animal management practices [55, 56], though some stud-
ies found no difference between species [22, 56]. Finally, the risk of seropositivity in livestock
increased with proximity to water points [43] and, hence, presumably to vectors. Another
study found contradictory results, but this was explained by cattle movement back to pens dur-
ing early evening which is where exposure to mosquitoes and, hence, RVFV was believed to
take place [76].
This systematic review sought to highlight important trends and gaps in RVFV seropreva-
lence in Africa and address where the risk factors lie in cross-species transmission events. In
particular, few studies to date have sampled humans, wildlife or livestock species concurrently.
This demonstrates that future medical and veterinary research should adopt a “One Health”
approach by performing concurrent livestock and human studies as well as assessing spillover
events between wildlife and livestock. Understanding the epidemiology and immunology of
RVFV in different species will aid targeting control measures such as vaccination to priority
species [17] and geographical areas, helping livestock workers in their economic and health
prosperity.
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